Received Aug 14, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
late second dose/got their 1st dose in Dec 2024, 2nd dose in May 2025; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a male patient who received HAB (Twinrix) for prophylaxis. Previously administered products included Twinrix (1st dose received in DEC-2024). In MAY-2025, the patient received the 2nd dose of Twinrix. In MAY-2025, an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too long (Verbatim: late second dose/got their 1st dose in Dec 2024, 2nd dose in May 2025). The outcome of the drug dose administration interval too long was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 29-JUL-2025 and 30-JUL-2025 The reporter reported a patient was late for his second dose of Twinrix due to being out of the country, which led to lengthening of vaccination scheduled. The 3rd dose of Twinrix had not yet been administered to the patient. This case had been linked to the case US2025097739, reported by the same reporter.; Sender's Comments: US-GSK-US2025097739:Same reporter/Diffrent patient